CROSS Sets New Benchmark with Transparent and Fair Token Launch
Opengame Foundation Completes Public Sale of CROSS Token, Burns Unsold Supply to Ensure Transparency and Value Stability
ZUG, CH / ACCESS Newswire / May 28, 2025 / Opengame Foundation (OGF), the non-profit organization behind the open blockchain gaming platform CROSS, has officially concluded its public token sale for the CROSS utility token.
The public sale, which ran for one week starting May 15, drew attention across the Web3 industry for its unique commitment to fairness and transparency. Tokens were offered at a fixed price of $0.10, the same as in the private sale, ensuring that all participants-whether early backers or new supporters-had access under identical conditions.
In total, 96 million CROSS tokens, representing 9.6% of the platform's total supply of 1 billion, were made available during the public sale on a first-come, first-served basis. Approximately 92% of the allocation was sold by the end of the sale period. The remaining unsold tokens will be permanently burned-a move designed to reinforce both the integrity of the token's value and the foundation's long-term commitment to transparency.
Henry Chang, CEO of NEXUS and key contributor to the CROSS ecosystem, described the initiative as 'an unprecedented experiment.' In a post on X (formerly Twitter), he wrote:
'Another dot, placed. We've now completed an unprecedented experiment-offering the same price to private and public investors, including the founder and team ourselves. I appreciate the support and investment from all who believed in us.
Time will reveal how this unfolds. As we head toward the next milestone, TGE, we'll keep doing what we've always done: Build-so that one day, we can connect the dots backward.'
The Opengame Foundation plans to distribute CROSS tokens to public sale participants in accordance with the TGE timeline. Together with NEXUS, it will accelerate the growth of the CROSS ecosystem, bringing more developers and players into the open blockchain gaming space.
About Opengame Foundation
Opengame Foundation (OGF) is a non-profit organization committed to building an open and inclusive blockchain gaming ecosystem. As the steward of the CROSS Protocol, OGF aims to empower both developers and players by providing transparent infrastructure, fair tokenomics, and interoperable tools that support the next generation of Web3 games. With a focus on long-term sustainability, openness, and community participation, the foundation works to democratize access to digital assets and reshape how value is created and shared in the gaming world.
https://opengamefoundation.org
https://to.nexus
Media Contact
Organization: Opengame Foundation
Contact Person Name: Doyi Kim
Website: https://opengamefoundation.org
Email: [email protected]
Country: Switzerland
SOURCE: Opengame Foundation
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Alvotech (ALVO) Announces a Commercialization Agreement With Advanz Pharma
Alvotech (NASDAQ:ALVO) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, Alvotech (NASDAQ:ALVO) and Advanz Pharma announced a commercialization agreement to distribute and supply AVT10, a biosimilar candidate to Cimzia, in Europe. A scientist in a laboratory working on drug research. The agreement is expected to support Alvotech's (NASDAQ:ALVO) strategic position in the biosimilar market while allowing increased access to high-quality biologics in Europe. This could potentially affect the market share of the current treatments in the chronic rheumatic diseases sector. Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. Headquartered in Luxembourg, the company operates in the following geographical segments: Europe, North America, Asia, and Other. While we acknowledge the potential of ALVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
HubSpot Expands CRM Expertise Through Partnership with MatrixPoint
HubSpot Inc. (NYSE:HUBS) is one of the best NYSE stocks to buy for long term investment. As May was coming to an end, MatrixPoint announced its collaboration with HubSpot by joining its Solutions Partner Program. The partnership will enhance customer engagement and expand CRM/Customer Relationship Management expertise. The HubSpot Solutions Partner Program is a global network of experts providing services in marketing, sales, customer service, web design, CRM, and IT. This ecosystem emphasizes a customer-first approach for growth, which enables its members, like MatrixPoint, to offer a wider range of sophisticated solutions. A team of software developers gathered around a monitor discussing a new CRM platform. MatrixPoint is a results-driven media consultancy that empowers businesses to achieve more through marketing transformation and strategic growth. It will specifically expand its CRM practice through this partnership to help clients better use their customer data for more intelligent and personalized engagement. HubSpot Inc. (NYSE:HUBS) provides a cloud-based CRM platform for businesses in the Americas, Europe, and the Asia Pacific. While we acknowledge the potential of HUBS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
